Cannabis Legislation Coming Into Force October 2018 – Practical and Operational Considerations
Bill C-45, an Act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts (the “Cannabis Act”) received Royal Assent on June 21, 2018 and is scheduled to come into force on October 17, 2018. In this interim period, while the provincial and territorial governments, among others, work to introduce and pass their respective legislation and regulations, existing and prospective industry participants must work to understand precisely how the Cannabis Act will be implemented when it comes into force in October.
Forthcoming Regulations
While the Cannabis Act legalizes recreational cannabis and sets up a broad mechanism for controlling and standardizing how cannabis is to be grown, distributed and sold, it does not provide a detailed regulatory scheme outlining the precise parameters within which cannabis business operators will legally access the market and conduct their operations.
Detailed regulations which will set out these parameters will be published as imminently as this week in the form of Regulations made under the Cannabis Act (the “Cannabis Act Regulations”). As indicated in November 2017, when Health Canada published the “Proposed Approach to the Regulation of Cannabis” (the “Proposed Approach”) to solicit comments and feedback, the Cannabis Act Regulations will not be published for further public comment. See our January 2018 Article, Developments in Cannabis: “Bye Bye Cole”, CSA Reconsiders, New Federal Regulatory Paper, Provincial Updates, and What to Watch for in 2018. Based on the Proposed Approach and subsequent updates, it is expected that the Cannabis Act Regulations will govern, among others, the following key areas:
- Licenses, permits and authorizations allowing individuals and companies to grow and sell cannabis;
- Security clearances for certain parties connected to licensed cannabis operators;
- A national cannabis tracking system;
- Packaging and labelling; and
- Health products and cosmetics with cannabis.
Key Practical and Operational Considerations
The passage of the Cannabis Act Regulations will require all individuals and companies operating or proposing to enter into the industry to review multi-faceted aspects of their business operations to ensure compliance with the new regulatory scheme and ensure rapid market entry. This review ought to encompass, at minimum, the following:
- Is your business ready to obtain a new license under the Cannabis Act and comply with the detailed requirements which will be particularized in the Cannabis Act Regulations? What kind of license is best suited for your proposed business given the introduction of new license types such as micro-sale, research, testing, and import and export?
- How will your business compete with micro-scale growers, and is this an area that your business should consider?
- Is your business ready to comply with security clearance requirements?
- Does your business comply with packaging and labelling requirements?
- Does your business have a robust marketing and branding plan, given the restrictions that will be imposed on the industry?
- What is the intellectual property strategy for your business? Is your business properly protecting its inventions and ready to adapt to new processes, methods and other innovations that are sure to come?
- Is your business ready to comply with Health Canada’s national seed-to-sale tracking system for cannabis?
Intimate knowledge of the Cannabis Act Regulations is essential to ensure that your business can rapidly obtain the necessary license approval and, when obtained, operate within the regulatory scheme to avoid jeopardizing the license.
Other Key Considerations
With the passage of the Cannabis Act, there will be legal risks (and opportunities) that arise upon implementation in October 2018. Business operators should consider all aspects of their operations to take advantage of these opportunities and to minimize any risks. This can be accomplished by undertaking regulatory review of operations, considering all aspects of intellectual property (including trade secrets, maintenance of proprietary information and patentability of newly developed strains of cannabis) and ensuring that marketing and distribution activities fully comply with the Cannabis Act and the Cannabis Act Regulations.
Over the coming months, Goodmans Cannabis Group will provide updates highlighting key provisions in the Cannabis Act and the Cannabis Act Regulations.
Goodmans Cannabis Group
Goodmans LLP has a leading cannabis practice in the corporate/commercial field, having been actively involved in the industry from the beginning. Our corporate cannabis lawyers have extensive knowledge of the various players in the industry and have provided strategic business advice on governance, financing, licensing, regulation, capital markets, mergers and acquisitions and real estate matters. Our clients include start-ups, importers and exporters, and financial institutions related to the cannabis industry.
In addition, Goodmans is uniquely positioned with its extensive regulatory, health and intellectual property practices to advise new and existing market entrants. In particular, given our extensive work with respect to “traditional” pharmaceuticals regulated under the Food and Drugs Act and its associated Regulations (legislation used, in part, as the model for the upcoming Cannabis Act Regulations), we uniquely understand the industry, are equipped to address regulatory concerns that may arise, and know how to best protect and enforce our clients’ intellectual property. This includes matters such as licensing and regulation in the industry’s preliminary stages and future issues that may arise with regulators and competitors, including with respect to labelling and packaging, patent and trademark applications and prosecutions and the protection of trade secrets and confidential information.
Expertise
Authors
Insights
-
Cannabis
World Law Group 2020 Cannabis Guide
Victor Liu, Neil Sheehy and Danielle Levesque are contributors to the Canada section of the World Law Group 2020 Cannabis Guide. The Guide covers legislation, governing bodies, import and export… -
Cannabis
CSA Further Scrutinizes Disclosure by Cannabis Reporting Issuers
On November 12, 2019, the Canadian Securities Administrators (CSA) published Staff Notice 51-359 (the “Staff Notice”), highlighting inadequacies in disclosure of financial interests in M&A… -
Cannabis
Legal Landscape Applicable to the Regulation of Cannabis in Canada
On April 13, 2017, the Government of Canada introduced Bill C-45, the Cannabis Act, in the House of Commons. Based on the input of public health, law enforcement and justice experts, the Cannabis Act… -
Cannabis
Ontario Retail Cannabis Update… The Limited-Licence Lottery System
On December 13, the Ontario government announced significant changes to the province’s planned rollout of its retail cannabis regime. Ontario made regulation 497/18 (the “Amending Regulation”) under… -
Cannabis
Ontario Retail Cannabis Update"¦New Rules Rolled Out for Future Cannabis Retailers
The Alcohol and Gaming Commission (AGCO) released its Registrar’s Standards (the “Standards”) which provide further operational rules for cannabis retailers in Ontario. As detailed in our November… -
Cannabis
Ontario (Late to the Party) Retail Cannabis Update… With More to Come…
On October 17, 2018, Ontario enacted the Cannabis Licence Act (CLA) to permit the sale of recreational cannabis in privately owned stores. The CLA and its regulations, the Cannabis Licence Regulations…
Featured Work
-
Cannabis
Organigram acquires Sanity Group
Goodmans LLP advised Organigram Global Inc. (the “Company” or “Organigram”), a leading licensed producer of cannabis, in connection with its acquisition of Sanity Group GmbH (“Sanity” or “Sanity… -
Cannabis
Organigram Holdings Inc. receives $124 million investment from BT DE Investments Inc.
Goodmans LLP advised Organigram Holdings Inc., the parent company of Organigram Inc., a leading licensed producer of cannabis, in connection with its C$124.6 million follow-on strategic equity… -
Restructuring
Ayr Wellness cross-border restructuring
Goodmans LLP acted as Canadian counsel to the Ad Hoc Committee Senior Noteholders of Ayr Wellness Inc. and Ayr Wellness Canada Holdings Inc. in connection with the negotiation and structuring of the… -
Restructuring
Wayland Group CCAA restructuring
Goodmans LLP represented the senior creditors in connection with the CCAA restructuring of Wayland Group and the acquisition of its operating business by Ring… -
Restructuring
MJardin’s restructuring proceedings
Goodmans LLP acted for KSV Restructuring Inc. (“KSV”) in respect of MJardin Group, Inc. (“MJardin” or the “Company”), a publicly traded licensed Canadian cannabis producer, in its restructuring… -
Capital Markets
Medicine Man Technologies NEO Listing
Goodmans LLP acted for Medicine Man Technologies, Inc., dba Schwazze (OTCQX: SHWZ) (NEO: SHWZ) in connection with their listing of common shares on the NEO Exchange – a tier one Canadian stock…
News & Events
-
Banking and Financial Services
Goodmans Receives Top-Tier Recognition from The Legal 500 Canada 2026
We are pleased to announce Goodmans has once again received top-tier recognition from The Legal 500 Canada in their 2026 Guide.Recognition from The Legal 500 is based on independent research and… -
Banking and Financial Services
Goodmans Recognized in the Best Law Firms - Canada 2026
Goodmans is pleased to share we are once again featured in the Best Law Firms - Canada 2026, recognizing us as one of Canada’s most exceptional law firms across 42 industries and practices.We are also… -
Aging and Healthcare
Goodmans Honoured Again with Top-Tier Recognition from Chambers and Partners
We are delighted to announce Goodmans LLP continues to receive top-tier recognition from Chambers and Partners in the Chambers Canada 2026 Guide.Recognition from Chambers and Partners is based on…